Grifols (GRFS) Income from Non-Controlling Interests (2010 - 2023)
Grifols' (GRFS) quarterly Income from Non-Controlling Interests came in at $130569.6 in Q4 2023, up 103.57% YoY from $64139.9 in Q4 2022, and up 103.57% on a QoQ basis from $64139.9 in Q4 2022.
Grifols (GRFS) Income from Non-Controlling Interests (2010 - 2023) Analysis & Trends
Grifols (GRFS) has 13 years of Income from Non-Controlling Interests data on file, last reported at $130569.6 in Q4 2023.
- Quarterly Income from Non-Controlling Interests rose 103.57% year-over-year to $130569.6 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$18.6 million (down 11.57% YoY) and the FY2025 annual result came in at $114.1 million, up 90.63% from the prior year.
- Income from Non-Controlling Interests advanced to $130569.6 in Q4 2023, from $64139.9 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $130569.6 in Q4 2023 to a low of -$18.9 million in Q1 2020.
- A 4-year average of -$4.7 million and a median of $82649.9 in 2019 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2019 — Income from Non-Controlling Interests soared 115.33% — and 2020, when it sank 18826.37%.
- Tracing GRFS's Income from Non-Controlling Interests over 4 years: stood at $101160.0 in 2019, then slumped by 18826.37% to -$18.9 million in 2020, then jumped by 100.34% to $64139.9 in 2022, then jumped by 103.57% to $130569.6 in 2023.
- The last three Income from Non-Controlling Interests figures came in at $130569.6 (Q4 2023), $64139.9 (Q4 2022), and -$18.9 million (Q1 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -2.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -7.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 10.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 741.95 Mn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 130,569.61 |
| Dec 31, 2022 | 64,139.89 |
| Mar 31, 2020 | -18.94 Mn |
| Mar 31, 2019 | 101,159.97 |
| Dec 31, 2018 | 2.06 Mn |
| Jun 30, 2018 | 668,328.87 |
| Mar 31, 2018 | -659,722.11 |
| Dec 31, 2017 | -1.22 Mn |
| Jun 30, 2017 | 256,194.99 |
| Mar 31, 2017 | -274,874.98 |
| Dec 31, 2016 | -353,069.82 |
| Sep 30, 2016 | 256,722.43 |
| Jun 30, 2016 | 325,404.01 |
| Dec 31, 2015 | -1.98 Mn |
| Sep 30, 2015 | 201,323.57 |
| Jun 30, 2015 | -278,495.60 |
| Mar 31, 2015 | -754,728.11 |
| Dec 31, 2014 | 833,638.93 |
| Sep 30, 2014 | 848,139.23 |
| Jun 30, 2014 | 721,604.52 |